Increasing numbers of clinical studies indicate that antibodies targeting PD-1 or PD-L1 can achieve promising results in multiple tumor types [2,9], including melanoma, prostate cancer, and non-small cell lung cancer (NSCLC) [10,11,12]. Here, CD274 is linked to non-small cell lung carcinoma.